Skip to main content

Company

STADA

10 published works

  1. Big Molecule Watch

    STADA and SBP Group Launch Biosimilars Partnership

    By Michael Shriner

    STADA and Sino Biopharmaceutical Limited (“SBP Group”), through its subsidiary Chia Tai Tianqing Pharmaceutical Group (“CTTQ”), have entered into a partnership to manufacture, market, and sell biosimilars. CTTQ will develop,…

  2. Big Molecule Watch

    European Biosimilar Updates

    By Allegra Padula

    On February 13, 2026, STADA and Bio-Thera announced that they have received European Marketing Authorization for GOTENFIA®, a golimumab biosimilar to Johnson & Johnson’s SIMPONI®.  GOTENFIA® is a human monoclonal…

  3. Big Molecule Watch

    European Biosimilar Updates – Alvotech/Advanz’s MYNZEPLI Approval and Bio-Thera/STADA Tocilizumab Alliance

    By Darlene Staines

    On August 21, 2025, Alvotech and Advanz Pharma Holdco Limited (“Advanz”) announced that MYNZEPLI®, a biosimilar of Regeneron’s EYLEA® (aflibercept), was approved by the European Commission.  MYNZEPLI® will be available…

  4. Big Molecule Watch

    STADA and Alvotech Announce Launch of UZPROVO® in Europe

    By Tara Thigpen

    On July 22, 2024, STADA Arzeimittel AG (“STADA”) and Alvotech announced the launch of ustekinumab biosimilar AVT04 under the name UZPROVO® across a majority of European countries. UZPROVO®, the first…

  5. Litigation Finance Journal

    SdK Offers Litigation Finance to Enforce Claims for Additional Payment for Former Shareholders of STADA Arzneimittel AG

    By John Freund

    Former shareholders of STADA Arzneimittel AG who tendered their Stada shares as part of the takeover offer by Nidda Healthcare Holding AG in August or September 2017 are entitled to…

  6. Big Molecule Watch

    Alvotech and STADA obtain approval in Europe for ustekinumab biosimilar, UZPRUVO

    By Daniel Farraye

    On January 10, Alvotech announced that the European Commission (EC) issued a marketing authorization to its European commercialization partner, STADA, for UZPRUVO (AVT04), a biosimilar referencing STELARA (ustekinumab). The authorization…

  7. Big Molecule Watch

    European Biosimilar Regulatory Updates

    By Lihui Bai

    STADA and Xbrane Announce Approval of Ranibizumab Biosimilar in UK On January 16, 2023, STADA Arzneimittel AG (STADA) and Xbrane Biopharyma AB (Xbrane) announced that the UK’s Medicines and Healthcare…

  8. Big Molecule Watch

    Alvotech Broadens Access to HUMIRA (adalimumab) Biosimilars

    By Yoko Bian

    Alvotech announced yesterday the launch of HUKYNDRA, a high-concentration, low-volume, citrate-free biosimilar to HUMIRA (adalimumab), in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia.  Through a strategic partnership with…

  9. Big Molecule Watch

    Alvotech and STADA Launch HUKYNDRA® (Biosimilar of HUMIRA®) in Europe

    By Audie Soucy

    Alvotech and Stada recently announced the launch of HUKYNDRA® to patients in certain European countries, including France, Germany, Finland, and Sweden.  HUKYNDRA® is a biosimilar of HUMIRA® (adalimumab) developed by…

  10. Big Molecule Watch

    STADA and Xbrane Ink Commercialization Deal with Bausch + Lomb for LUCENTIS Biosimilar Candidate

    By Big Molecule Watch

    On May 6, 2020, Bausch + Lomb and co-development partners STADA and Xbrane announced that they have entered into an exclusive licensing agreement with one another under which Bausch +…